Phase 2 ARB Clinical Trials
24 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 24 trials
Recruiting
Phase 1Phase 2
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency DiseaseUrea Cycle Disorders, Inborn+1 more
iECURE, Inc.20 enrolled12 locationsNCT06255782
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Solid TumorsHGGCancer Harboring BRAF Alterations+1 more
Fore Biotherapeutics254 enrolled67 locationsNCT05503797
Recruiting
Phase 2
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Phase 1Phase 2
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
ARBBVMDAutosomal-Dominant Bestrophinopathy+1 more
Opus Genetics, Inc10 enrolled4 locationsNCT07185256
Recruiting
Phase 2
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Ann Arbor Stage II Follicular LymphomaGrade 1 Follicular LymphomaAnn Arbor Stage III Follicular Lymphoma+6 more
University of Washington20 enrolled1 locationNCT06442475
Recruiting
Phase 2
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Solid Tumors Harboring MET Amplification
AbbVie125 enrolled26 locationsNCT07196644
Recruiting
Phase 2
PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma+1 more
M.D. Anderson Cancer Center31 enrolled1 locationNCT04745949
Recruiting
Phase 1Phase 2
A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.
Healthy ParticipantsSarbecovirus
SK Bioscience Co., Ltd.368 enrolled2 locationsNCT07280858
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
Solid Tumors Harboring NTRK FusionNTRKNTRK Gene Fusion+1 more
Cullgen (Shanghai),Inc42 enrolled6 locationsNCT07394374
Recruiting
Phase 1Phase 2
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
Platinum Resistant Ovarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
TILT Biotherapeutics Ltd.29 enrolled3 locationsNCT05271318
Recruiting
Phase 2
CO2 Modulation in Endovascular Thrombectomy for Acute Ischemic Stroke
ThrombectomyIschemic Stroke, AcuteCerebrovascular Circulation+2 more
University Hospital, Clermont-Ferrand50 enrolled1 locationNCT05051397
Recruiting
Phase 1Phase 2
HP Pyruvate MRI in Cancers
ImageTumorsWarburg Effect
University of Maryland, Baltimore25 enrolled1 locationNCT05697406
Recruiting
Phase 1Phase 2
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Advanced Solid Tumors Harboring NTRK FusionPrimary Central Nervous System Tumors Harboring NTRK Fusion
Beijing InnoCare Pharma Tech Co., Ltd.70 enrolled1 locationNCT05745623
Recruiting
Phase 2
Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy
Jian Chen48 enrolled1 locationNCT06186726
Recruiting
Phase 2
Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor
Radiotherapy Side EffectThymic Epithelial TumorCarbon Ion Radiotheray+1 more
Jian Chen48 enrolled1 locationNCT06311955
Recruiting
Phase 2
Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
Radiotherapy Side EffectNon-small Cell Lung CancerOlder People+1 more
Jian Chen29 enrolled1 locationNCT06311981
Recruiting
Phase 2
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
Ann Arbor Stage II Follicular LymphomaGrade 1 Follicular LymphomaAnn Arbor Stage III Follicular Lymphoma+3 more
Joseph Tuscano40 enrolled4 locationsNCT04450173
Recruiting
Phase 2
A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD
Ornithine Transcarbamylase DeficiencyOTC DeficiencyOTCD
Arcturus Therapeutics, Inc.9 enrolled1 locationNCT06488313
Recruiting
Phase 2
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
Non-small Cell Lung CancerAntineoplastic AgentsEGFR+5 more
Peng Zhang60 enrolled1 locationNCT06755684
Recruiting
Phase 2
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Ann Arbor Stage II Follicular LymphomaGrade 1 Follicular LymphomaAnn Arbor Stage III Follicular Lymphoma+3 more
Chinese PLA General Hospital30 enrolled1 locationNCT06471738